ELDN stock Statistics — Eledon Pharmaceuticals, Inc. filings, insiders & smart money

Price and daily changeSign in

Earnings13 Nov 2026

52-week rangeSign inDay rangeSign in

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2026-08-10 · filed common shares: 81.26M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.67%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 9.53%
Short ratioDays to cover, as published by FINRA: 8.08
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 68.80%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 63.30%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -236.51%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -72.74%

Sign in

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

-0.90

EPS (fwd)

Cash & equivalentsas of Jun 26: $6.80M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $467.00K
Debt / equityas of Jun 26: 1.41%
Current ratioas of Jun 26: 7.90
Quick ratio: —
Operating cash flowTTM to Jun 26: -$73.85M
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: -$73.85M
TTM revenue / diluted share: —